Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2010, Vol. 4 Issue (4) : 430-435     DOI: 10.1007/s11684-010-0700-7
Research articles |
Influence of the adjuvant therapy on the survival of patients with stage II pancreatic carcinoma
Xi-Yan WANG1,Hai-Jun LI1,Dong YAN1,Hao WEN2,Shu-Yong PENG3,
1.Department of Hepatopancreatobiliary Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi 830011, China; 2.Department of Hepatobiliary Surgery, The First Affiliated Hospital, Xinjiang Medical University, Urumqi 830054, China; 3.Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China;
Download: PDF(205 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  This study aimed to investigate the effect of adjuvant therapy on the treatment of stage II pancreatic carcinomas. The clinical data of 139 cases of stage II pancreatic carcinoma were analyzed retrospectively. The overall 1-, 3-, and 5-year cumulative survival rates of 139 patients were 40%, 6%, and 3%, respectively, and the median survival time (MST) was 279 days. The MST was 399 days for those with adjuvant therapy, 210 days for those without adjuvant therapy, 390 days for the radical resection group, 270 days for the bypass operation and laparotomy group, and 132 days for the nonsurgical group. The adjuvant therapy could not prolong the survival time and decrease the liver metastasis rate of the patients with stage II carcinoma significantly in radical resection group (P>0.05). In the bypass operation and laparotomy group and nonsurgical group, the adjuvant therapy could improve the survival of the patients significantly (P<0.05); however, the survival rate was not significantly different among systemic venous chemotherapy, radiation therapy, interventional therapy, and combination therapy (P>0.05); or between gemcitabine (GEM) regimen and 5-fluorouracil regimen (P>0.05); or between GEM monotherapy and GEM combined with platinum/capecitabine (P>0.05). The proper adjuvant therapy can be suggested according to the general condition of the patients after radical resection for stage II pancreatic carcinoma. Chemotherapy combined with radiation should be applied actively for the patients whose cancerous tissues were not radically resected. The clinical efficacy of GEM combined with platinum/capecitabine is relatively better than GEM.
Keywords pancreatic neoplasms      neoadjuvant therapy      survival      
Issue Date: 05 December 2010
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0700-7     OR     http://academic.hep.com.cn/fmd/EN/Y2010/V4/I4/430
Kern S, Hruban R, Hollingsworth M A, Brand R, Adrian T E, Jaffee E, Tempero M A. A white paper: the product of a pancreas cancer thinktank. Cancer Res, 2001, 61(12): 4923–4932
PMID: 11406572
Au E. Clinical update of gemcitabine in pancreas cancer. Gan To Kagaku Ryoho, 2000, 27(Suppl 2): 469–473
PMID: 10895197
Wagner M, Redaelli C, Lietz M, Seiler C A, Friess H, Büchler M W. Curative resection is thesingle most important factor determining outcome in patients withpancreatic adenocarcinoma. Br J Surg, 2004, 91(5): 586–594 doi:10.1002/bjs.4484
PMID:

doi: 10.1002/bjs.4484
15122610

doi: 10.1002/bjs.4484
Yekebas E F, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist Y K, Schurr P G, Liebl L, Thieltges S, Gawad K A, Schneider C, Izbicki J R. En bloc vascular resection for locally advanced pancreatic malignanciesinfiltrating major blood vessels: perioperative outcome and long-termsurvival in 136 patients. Ann Surg, 2008, 247(2): 300–309 doi:10.1097/SLA.0b013e31815aab22
PMID:

doi: 10.1097/SLA.0b013e31815aab22
18216537

doi: 10.1097/SLA.0b013e31815aab22
Sun C Y, Chen Z L. Attach Importance of Combined Modality Therapy for Pancreatic Carcinomas. Zhonghua Xiao Hua Wai Ke Za Zhi, 2009, 8(4): 244–246 (in chinese)
Cheng D H, Liu Y F. TNM staging of pancreatic carcinomas. Zhongguo Shi Yong Wai Ke Za Zhi, 2004, 24(5): 320 (in chinese)
Wu W D, Peng C H, Zhao D J, Zhou G W, Xiao W D, Li H W. The importance of superior mesenteric-portal vein resectionfor radical duodenopancreatectomy of pancreatic adenocarcinoma. Zhonghua Pu Tong Wai Ke Za Zhi, 2006, 21(9): 620–622 (in chinese)
Qin R Y, Zou S Q, Qiu F Z. The technique of radical pancreaticoduodenectomyfor malignant tumor in pancreatic head with pressed superior mesentericblood vessels or portal vein. Zhonghua Wai Ke Za Zhi, 2008, 46(5): 366–369 (in chinese)
PMID: 18785534
Cress R D, Yin D, Clarke L, Bold R, Holly E A. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control, 2006, 17(4): 403–409 doi:10.1007/s10552-005-0539-4
PMID:

doi: 10.1007/s10552-005-0539-4
16596292

doi: 10.1007/s10552-005-0539-4
Saif M W. Is there a standard of care for the management of advancedpancreatic cancer? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25―27, 2008. JOP, 2008, 9(2): 91–98
PMID: 18326919
Wray C J, Ahmad S A, Matthews J B, Lowy A M. Surgery for pancreatic cancer: recent controversies andcurrent practice. Gastroenterology, 2005, 128(6): 1626–1641 doi:10.1053/j.gastro.2005.03.035
PMID:

doi: 10.1053/j.gastro.2005.03.035
15887155

doi: 10.1053/j.gastro.2005.03.035
Saif M W. Pancreatic cancer: highlights from the 42nd annual meetingof the American Society of Clinical Oncology, 2006. JOP, 2006, 7(4): 337–348
PMID: 16832131
Neoptolemos J P, Stocken D D, Friess H, Bassi C, Dunn J A, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr D J, Büchler M W. A randomized trial of chemoradiotherapyand chemotherapy after resection of pancreatic cancer. N Engl J Med, 2004, 350(12): 1200–1210 doi:10.1056/NEJMoa032295
PMID:

doi: 10.1056/NEJMoa032295
15028824

doi: 10.1056/NEJMoa032295
Hosch S B, Knoefel W T, Metz S, Stoecklein N, Niendorf A, Broelsch C E, Izbicki J R. Early lymphatic tumor cell dissemination in pancreaticcancer: frequency and prognostic significance. Pancreas, 1997, 15(2): 154–159 doi:10.1097/00006676-199708000-00007
PMID:

doi: 10.1097/00006676-199708000-00007
9260200

doi: 10.1097/00006676-199708000-00007
Tawada K, Yamaguchi T, Kobayashi A, Ishihara T, Sudo K, Nakamura K, Hara T, Denda T, Matsuyama M, Yokosuka O. Changes in tumor vascularity depicted by contrast-enhanced ultrasonographyas a predictor of chemotherapeutic effect in patients with unresectablepancreatic cancer. Pancreas, 2009, 38(1): 30–35 doi:10.1097/MPA.0b013e318183ff73
PMID:

doi: 10.1097/MPA.0b013e318183ff73
19117085

doi: 10.1097/MPA.0b013e318183ff73
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein W O, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy withgemcitabine vs observation in patients undergoing curative-intentresection of pancreatic cancer: a randomized controlled trial. JAMA, 2007, 297(3): 267–277 doi:10.1001/jama.297.3.267
PMID:

doi: 10.1001/jama.297.3.267
17227978

doi: 10.1001/jama.297.3.267
Jin C, Yao L, Long J, Fu D L, Yu X J, Xu J, Yang F, Ni Q X. Effect of multiple-phase regional intra-arterialinfusion chemotherapy on patients with resectable pancreatic headadenocarcinoma. Chin Med J (Engl), 2009, 122(3): 284–290
PMID: 19236805
Sultana A, Smith C T, Cunningham D, Starling N, Neoptolemos J P, Ghaneh P. Meta-analyses of chemotherapyfor locally advanced and metastatic pancreatic cancer. J Clin Oncol, 2007, 25(18): 2607–2615 doi:10.1200/JCO.2006.09.2551
PMID:

doi: 10.1200/JCO.2006.09.2551
17577041

doi: 10.1200/JCO.2006.09.2551
[1] Xinsen Xu,Kai Qu,Qing Pang,Zhixin Wang,Yanyan Zhou,Chang Liu. Association between telomere length and survival in cancer patients: a meta-analysis and review of literature[J]. Front. Med., 2016, 10(2): 191-203.
[2] Lan Wang,Jueheng Wu,Jie Yuan,Xun Zhu,Hongmei Wu,Mengfeng Li. Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo[J]. Front. Med., 2016, 10(1): 41-51.
[3] Yunfeng Fu, Xinyu Wang, Zimin Pan, Xing Xie. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases[J]. Front Med, 2014, 8(1): 91-95.
[4] Renling Pei, Ye Xu, Yan Wei, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie. Association of SIPA1 545 C>T polymorphism with survival in Chinese women with metastatic breast cancer[J]. Front Med, 2013, 7(1): 138-142.
[5] Qinggang Hu, Shanglong Liu, Jianwei Jiang, Chen Zhang, Xiaowei Liu, Qichang Zheng. Potential indicators predict progress after surgical resection of gastrointestinal stromal tumors[J]. Front Med, 2012, 6(3): 317-321.
[6] Jiong HU. Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction[J]. Front Med, 2011, 5(1): 45-52.
[7] ZOU Yunfeng, NIU Piye, GONG Zhiyong, YANG Jin, YUAN Jing, WU Tangchun, CHEN Xuemin. Relationship between reactive oxygen species and sodium-selenite-induced DNA damage in HepG2 cells[J]. Front. Med., 2007, 1(3): 327-332.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed